Photo: Courtesy of Teva
16 March 2017Americas

Teva and Actavis taken to court over acne drug

Dow Pharmaceutical Sciences and Valeant Pharmaceuticals have sued Teva and its subsidiary Actavis for patent infringement of Onexton (clindamycin phosphate and benzoyl peroxide), a treatment for acne.

The  case, which was filed on Tuesday, March 14 at the US District Court for the District of New Jersey, arose after Actavis filed an Abbreviated New Drug Application.

According to the claim, Actavis informed Dow in March that it was seeking Food and Drug Administration approval to market a generic version of the acne treatment.

The patents involved in the case are US numbers 9,504,704 and 9,561,208.

Dow, the owner of both patents, and Valeant have asked the district court to enter a judgment that Teva and Actavis have infringed the patents.

The companies have also asked the court for Teva and Actavis to be enjoined from bringing the generic to market, as well as an award of costs.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at